OvaGene Oncology Selected as one of the “Top 50 Emerging Companies” by Venture Capital
Funds and Angel Investors
FOR IMMEDIATE RELEASE
Irvine, Calif/PRNewswire/June 24, 2011-- OvaGene Oncology Inc., a biotechnology company specializing in the development
and commercialization of personalized gene-based diagnostics for gynecologic cancer, announced today that the company was
th
honored as one of the “50 Top Emerging Companies” in FundingPost’s 7 Annual “Pitch Across America” competition.
The “Pitch Across America” competition is the largest national competition of its kind. Hundreds of emerging companies were
evaluated by 100+ Venture Capitalists and Angel Investors across the country who participate as judges and vote on the
emerging companies potential for success. Each company was judged in several key areas including executive summary
professionalism, current stage of development (customers, revenue), competitive advantage and need in the marketplace,
feasibility for success, and whether the company is “VentureWorthy.™” FundingPost has been introducing entrepreneurs to
investors for almost ten years. This was the largest Venture Capital competition ever organized and was sponsored by PR
Newswire, YouTern, Reitler Kailas & Rosenblatt, and Daymond John of ABC’s Shark Tank.
"It is very gratifying to be recognized as a top emerging company”, stated Jay Coonan, M.D., Executive Vice President, Strategy
and Business Development, “OvaGene is an innovative, high quality start-up company with the potential to secure capital
based on its strong competitive advantage in the marketplace and strong business strategy. Our experienced senior
management team looks forward to working with investors to build a highly successful oncology diagnostics company."
Ovagene is seeking additional investment for the commercialization and future market expansion for its molecular gynecologic
cancer diagnostic assays. OvaGene has a rich pipeline of both proprietary and non-proprietary diagnostic products under
development over the next 5 -7 years. Early capital investment in the company will accelerate research/commercialization
efforts and fast-track profitability.
About OvaGene Oncology
OvaGene Oncology is a molecular diagnostics company, located in Orange County California, dedicated to improving cancer
care and outcomes for gynecologic cancer patients through the development of novel gene-based assays. The company plans
to offer proprietary and non-proprietary molecular diagnostic assays to assist physicians in the prognosis of gynecologic cancers
as well as therapy selection, including radiation and chemotherapy. There are over 11,000 cases of cervical cancer, 25,000
cases of ovarian cancer and 42,000 cases of endometrial cancer diagnosed each year in the United States. The total market for
OvaGene’s genomic assays is over 80,000 gynecologic cancer cases diagnosed annually. Please visit our website at
www.ovagene.com for more information about our company.
About FundingPost.com
We are the single largest venture exchange in the country. We work with more Real Accredited Angel Investors, VC Firms and
entrepreneurs than anyone else. We have a dedicated team that works hard to make introductions every single day. With over
9,500 CEOs and 650 Venture Capital Funds attending events in 19 cities nationwide; a Printed Dealflow Magazine; and a deal-
exchange website with over 7,600 VC and Angel Investor members and over 130,000 companies, that has, on average, made an
introduction of an Investor to an Entrepreneur every business day since its inception; FundingPost believes that it is important
to reach investors in every medium possible - both online and offline. FundingPost has been responsible for Millions and
Millions of dollars in Venture Capital Raised! Please visit www.fundingpost.com for more information.
Contact:
OvaGene Oncology
Jay Coonan, M.D.
Executive Vice President, Strategy and Business Development
e-mail: jcoonan@ovagene.com
Phone: 480-544 9257